Creative Biolabs, a global leader in antibody engineering, has announced the expansion of its integrated suite of solutions focused on antibody-dependent cellular cytotoxicity (ADCC).
SHIRLEY, NY, April 22, 2026 /24-7PressRelease/ — By combining proprietary glyco-engineering technologies with standardized bioanalytical validation, Creative Biolabs is accelerating the transition from biosimilars to high-potency “biobetters,” addressing the industry’s critical need for reproducible anti-tumor efficacy.
Overcoming the “Fucose Barrier” in Antibody Potency
The clinical success of monoclonal antibodies (mAbs) often hinges on their ability to recruit immune effector cells. However, the presence of fucose in the Fc region typically creates steric hindrance, limiting binding affinity to FcγRIIIa receptors. Creative Biolabs’ core innovation, the Afuco™ technology platform, utilizes targeted gene-editing tools like CRISPR-Cas9 and TALEN to produce non-fucosylated antibodies. This modification has been demonstrated to increase IgG affinity for FcγRIIIa by more than 100-fold, significantly amplifying the therapeutic window of oncology drugs.
“Precision in glycosylation is the cornerstone of next-generation immunotherapy,” stated a senior scientist at Creative Biolabs. “Our focus is not merely on production but on controlling the Bioprocess Quality by Design (QbD). By pinpointing glycosylation-related critical quality attributes (gCQA), we ensure that every batch of ADCC-enhanced biobetters meets rigorous stability and potency standards required for clinical transformation.”
Standardizing ADCC Analysis for Regulatory Compliance
One of the primary challenges in biologics development is the inherent variability of ADCC assays when using donor-derived primary cells. To mitigate this, Creative Biolabs has introduced a standardized therapeutic antibody analysis framework. This platform prioritizes Jurkat-based reporter gene assays over traditional PBMC methods, offering a consistent NFAT-mediated luciferase readout that eliminates donor-specific noise.
The analytical suite covers:
Glycan Profiling: High-resolution HILIC-UPLC analysis for fucose quantification.
Binding Kinetics: SPR and Octet-based real-time affinity measurements.
Purity & Stability: Comprehensive SDS-PAGE, SEC, and MS/MS sequencing to ensure structural integrity.
Strategic Infrastructure: Engineered Cell Lines
To support internal drug discovery and client-led validation, Creative Biolabs now offers an extensive catalog of specialized ADCC cell lines. This includes both effector cells stably expressing FcγRIIIa and a library of over 100 qualified tumor target cell lines (e.g., HER2+, CD20+, EGFR+). These tools allow researchers to establish robust, cGMP-compliant assay environments that are crucial for Investigational New Drug (IND) applications.
Technical Deep-Dive: FAQ Backgrounder
How does ADCC enhancement differ from traditional mAb production? While traditional mAbs rely on natural glycosylation, ADCC enhancement specifically targets the removal of core fucose. Creative Biolabs achieves this through host cell engineering (FUT8 knockout) rather than chemical treatment, ensuring the resulting antibodies remain native and stable while exhibiting superior effector function.
Why is the shift toward reporter assays significant? Traditional ADCC assays using primary NK cells are prone to inter-assay variability. Reporter cell lines provide a standardized biological response, allowing for precise potency quantification that is more easily validated for regulatory submissions.
About
Creative Biolabs is a premier provider of antibody discovery and engineering services. With decades of experience in Fc engineering and glycosylation, the company supports global pharmaceutical partners in developing high-efficacy therapeutics for cancer, infectious diseases, and autoimmune disorders.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
